Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion-LUNG 2 first-line zongertinib versus pembrolizumab plus platinum-pemetrexed in HER2-mutant non-squamous NSCLC
MOH_2024-02-14_013236Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Zongertinib with Standard of care (2 arms). Primary endpoint: Progression-free survival. Started Feb 2024; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-02-14_013236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-14_013236.